Surrozen Inc (SRZN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $602.54M
Last updated: Nov 17, 2026 at 11:06 AM ET
Surrozen Inc (SRZN) Competitors
The companies most similar to Surrozen are Indaptus Therapeutics (INDP), Gyre Therapeutics (GYRE) and Immix Biopharma (IMMX). By market cap, Surrozen ranks 8th of the 13 companies on this page; MoonLake Immunotherapeutics (MLTX) is the largest at $1.06B.
Peer Comparison
SRZN's revenue growth of 408.6% is above the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Surrozen (SRZN) | $602.54M | N/A | 36.1x | 0.0% | N/A | 408.6% | 0.00% |
| Indaptus Therapeutics Inc (INDP) | $422.38M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Gyre Therapeutics Inc. (GYRE) | $471.74M | N/A | 3.8x | -22.7% | N/A | 0.7% | 0.00% |
| Immix Biopharma Inc (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| OmniAb Inc. (OABI) | $716.17M | N/A | 15.7x | -108.1% | -17.5% | 78.3% | 0.00% |
| Neurogene Inc (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| Sagimet Biosciences Inc. Series A Common Stock (SGMT) | $735.18M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Sana Biotechnology Inc (SANA) | $605.26M | N/A | N/A | 0.0% | -46.8% | 0.0% | 0.00% |
| Candel Therapeutics Inc (CADL) | $486.37M | N/A | N/A | 0.0% | -43.5% | 0.0% | 0.00% |
| Kura Oncology Inc (KURA) | $713.90M | N/A | 8.0x | 0.0% | -1125.3% | 10.1% | 0.00% |
| Avalo Therapeutics Inc (AVTX) | $448.71M | N/A | N/A | 0.0% | N/A | -69.3% | 0.00% |
| Rigel Pharmaceuticals Inc (RIGL) | $837.18M | 14.2x | 2.8x | 106.6% | 16.7% | 16.5% | 0.00% |
| MoonLake Immunotherapeutics (MLTX) | $1.06B | N/A | N/A | 0.0% | -54.6% | 0.0% | 0.00% |
| Peer median | $631.18M | 14.2x | 5.9x | 0.0% | -36.0% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Surrozen, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Indaptus Therapeutics Inc (INDP) | Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms. | INDP competitors |
| Gyre Therapeutics Inc. (GYRE) | Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. | GYRE competitors |
| Immix Biopharma Inc (IMMX) | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology... | IMMX competitors |
| OmniAb Inc. (OABI) | OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform. | OABI competitors |
| Neurogene Inc (NGNE) | Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders... | NGNE competitors |
| Sagimet Biosciences Inc. Series A Common Stock (SGMT) | Sagimet Biosciences Inc. (SGMT) is an innovative biotechnology company focused on developing breakthrough treatments for metabolic diseases... | SGMT competitors |
| Sana Biotechnology Inc (SANA) | Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington. | SANA competitors |
| Candel Therapeutics Inc (CADL) | Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform... | CADL competitors |
| Kura Oncology Inc (KURA) | Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. | KURA competitors |
| Avalo Therapeutics Inc (AVTX) | Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved... | AVTX competitors |
| Rigel Pharmaceuticals Inc (RIGL) | Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. | RIGL competitors |
| MoonLake Immunotherapeutics (MLTX) | MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to advancing therapies for chronic inflammatory diseases through its proprietary drug... | MLTX competitors |
Frequently Asked Questions About SRZN
Who are Surrozen's main competitors?
The companies most similar to Surrozen include Indaptus Therapeutics (INDP), Gyre Therapeutics (GYRE), Immix Biopharma (IMMX), OmniAb (OABI) and Neurogene (NGNE), listed from the closest match.
Who is Surrozen's biggest competitor?
MoonLake Immunotherapeutics (MLTX) is the largest of the similar companies at $1.06B; Indaptus Therapeutics (INDP) is the closest match by business profile, size, sector and industry.
How does SRZN stock compare with its competitors?
SRZN's P/S is 36.1x against a peer median of 5.9x; its net margin is 0.0% against a peer median of 0.0%.
Which of Surrozen's competitors pays a higher dividend?
Surrozen pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Surrozen bigger than its competitors?
No. Surrozen is 8th by market cap among the 13 companies on this page; the largest is MoonLake Immunotherapeutics (MLTX) at $1.06B.
SRZN pages: Overview, Earnings, Forecast, Financials, Competitors